Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus A Mall

Showing results (61-70 of 352) with videos related to

Pageof 36
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 11, 2011
Pharmacological therapy for cystic fibrosis: from bench to bedsideFrédéric Becq, Marcus A Mall, David N Sheppard, et al.
Nature Chemical Biology|August 4, 2009
Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammationAmanda Cobos-Correa, Johanna B Trojanek, Stefanie Diemer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 18, 2016
Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapyJ Stuart Elborn, Jane Davies, Marcus A Mall, et al.
Annals of the American Thoracic Society|September 17, 2025
The Clinical, Psychosocial and Economic Burden of Cystic Fibrosis Lung Disease in the Era of CFTR Modulator TherapyIsabelle Fajac, Raksha Jain, Marcus A Mall, et al.
Current Opinion in Pharmacology|October 25, 2017
Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transportHongyu Li, Johanna J Salomon, David N Sheppard, et al.
The Journal of Allergy and Clinical Immunology|June 12, 2020
Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4<sup>+</sup> T lymphocytesJobst F Roehmel, Monday O Ogese, Alexander Rohrbach, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 10, 2024
Nasal lavage microbiome, but not nasal swab microbiome, correlates with sinonasal inflammation in children with cystic fibrosisJaehi Chung, Sébastien Boutin, Dario L Frey, et al.
Pediatric Pulmonology|June 17, 2025
Prenatal Elexacaftor/Tezacaftor/Ivacaftor Treatment Prevents Meconium Ileus, but Not Exocrine Pancreatic Insufficiency and Lung Disease in Infants With Cystic FibrosisPaulina E Aleksander, Stephanie Thee, Felix Doellinger, et al.
Molecular and Cellular Pediatrics|November 7, 2015
miRNA-221 is elevated in cystic fibrosis airway epithelial cells and regulates expression of ATF6Irene K Oglesby, Raman Agrawal, Marcus A Mall, et al.
American Journal of Respiratory and Critical Care Medicine|June 6, 2024
Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor TherapyLinus Piehler, Ralf Thalemann, Christine Lehmann, et al.
Pageof 36

Showing results (61-70 of 352) with videos related to

Sort By:
Pageof 36
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 11, 2011
Pharmacological therapy for cystic fibrosis: from bench to bedsideFrédéric Becq, Marcus A Mall, David N Sheppard, et al.
Nature Chemical Biology|August 4, 2009
Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammationAmanda Cobos-Correa, Johanna B Trojanek, Stefanie Diemer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 18, 2016
Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapyJ Stuart Elborn, Jane Davies, Marcus A Mall, et al.
Annals of the American Thoracic Society|September 17, 2025
The Clinical, Psychosocial and Economic Burden of Cystic Fibrosis Lung Disease in the Era of CFTR Modulator TherapyIsabelle Fajac, Raksha Jain, Marcus A Mall, et al.
Current Opinion in Pharmacology|October 25, 2017
Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transportHongyu Li, Johanna J Salomon, David N Sheppard, et al.
The Journal of Allergy and Clinical Immunology|June 12, 2020
Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4<sup>+</sup> T lymphocytesJobst F Roehmel, Monday O Ogese, Alexander Rohrbach, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 10, 2024
Nasal lavage microbiome, but not nasal swab microbiome, correlates with sinonasal inflammation in children with cystic fibrosisJaehi Chung, Sébastien Boutin, Dario L Frey, et al.
Pediatric Pulmonology|June 17, 2025
Prenatal Elexacaftor/Tezacaftor/Ivacaftor Treatment Prevents Meconium Ileus, but Not Exocrine Pancreatic Insufficiency and Lung Disease in Infants With Cystic FibrosisPaulina E Aleksander, Stephanie Thee, Felix Doellinger, et al.
Molecular and Cellular Pediatrics|November 7, 2015
miRNA-221 is elevated in cystic fibrosis airway epithelial cells and regulates expression of ATF6Irene K Oglesby, Raman Agrawal, Marcus A Mall, et al.
American Journal of Respiratory and Critical Care Medicine|June 6, 2024
Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor TherapyLinus Piehler, Ralf Thalemann, Christine Lehmann, et al.
Pageof 36